Mukka Proteins Ltd

Mukka Proteins Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue ₹508.9 Cr (+108% YoY), EBITDA ₹50.1 Cr (9.9% margin), PAT ₹17.7 Cr (3.5%). Targets ₹3,000+ Cr revenue by FY30.

Mukka Proteins Results Update

Mukka Proteins reported Q2 FY27 revenue up 108% YoY to Rs.5,088.70 Mn. The Oman facility began commercial production, adding 37,200 MTPA of capacity.

Oman facility manufacturing capacity

37200.0 MTPA

Mukka Proteins Acquisition Worth ₹2.13 Cr

Mukka Proteins' board approved revised terms to acquire 85,200 equity shares, a 46% stake, in Swachha Eco Solutions for up to Rs 2.13 Crore. The unlisted waste-management company is not a related party.

Value

₹2.13 Cr

Execution

Up to 31-03-2027

Mukka Proteins Other Announcement

Mukka Proteins filed its quarterly statement of deviation for funds raised through a preferential warrant issue, reporting no deviation. Utilisation of Rs. 11.75 Crore against the working capital object is shown for the quarter ended September 2026.

Mukka Proteins Q2 FY27 Results: Net Profit ₹17.7 Cr, Up 156.5% YoY

Mukka Proteins Ltd reported revenue from operations of ₹508.9 Cr (+108.1% YoY) and net profit of ₹17.7 Cr (+156.5% YoY) for Q2 FY27.

Key figure

Net profit ₹17.7 Cr · +156.5% YoY

Mukka Proteins Board Meeting Date

Mukka Proteins intimated a board meeting on 07 Nov 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window closure is also disclosed.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Mukka Proteins Other Announcement

The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.